Astrazeneca (AZN) Liabilities and Shareholders Equity (2009 - 2026)

Astrazeneca has reported Liabilities and Shareholders Equity for 18 years, with the latest figure at $115.8 billion in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 3.03% year-over-year to $115.8 billion in Q2 2026; TTM through Jun 2026 was $458.4 billion, a 7.19% increase from a year earlier, with the FY2025 full-year figure at $114.1 billion, up 9.65% from the prior year.
• Liabilities and Shareholders Equity was $115.8 billion for Q2 2026 at Astrazeneca, up from $114.0 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $115.8 billion in Q2 2026, with the low at $94.2 billion in Q3 2022.
• Average Liabilities and Shareholders Equity over 5 years is $103.9 billion, with a median of $103.2 billion recorded in 2024.
• The largest YoY upside for Liabilities and Shareholders Equity was 54.44% in 2022 against a maximum downside of 12.16% in 2022.
• Over 5 years, Liabilities and Shareholders Equity stood at $96.5 billion in 2022, then rose by 4.8% to $101.1 billion in 2023, then gained by 2.88% to $104.0 billion in 2024, then advanced by 9.65% to $114.1 billion in 2025, then climbed by 1.54% to $115.8 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $115.8 billion (Q2 2026), $114.0 billion (Q1 2026), and $114.1 billion (Q4 2025), per Business Quant data.